Get the Stockscreener App
7.93
3.29%
-0.27
After Hours:
7.93
Fennec Pharmaceuticals Inc stock is traded at $7.93, with a volume of 240.59K.
It is down -3.29% in the last 24 hours and up +3.52% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$8.20
Open:
$8.2
24h Volume:
240.59K
Relative Volume:
1.71
Market Cap:
$270.84M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-13.00
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
-7.90%
1M Performance:
+3.52%
6M Performance:
-11.89%
1Y Performance:
+17.48%
1-Day Range:
$7.905
$8.695
1-Week Range:
$7.88
$8.77
52-Week Range:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.93 | 280.06M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Finviz
Fennec, Tampa General launch real-world PEDMARK oncology study - TipRanks
Fennec (FENC) backs PEDMARK real-world study at Tampa General - Stock Titan
Dow Update: Why is Fennec Pharmaceuticals Inc stock going downJuly 2025 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Collaborates With TGH Cancer Institute for Pedmark Study - marketscreener.com
Fennec Pharmaceuticals Inc. and Tampa General Hospital Cancer Institute Initiate Clinical Research Collaboration - marketscreener.com
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute - GlobeNewswire
Fennec (NASDAQ: FENC) CFO acquires 1,191 common shares via award vesting - Stock Titan
Fennec Pharmaceuticals (FENC) director trades options and common shares - Stock Titan
Why (FENC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FENC (NASDAQ: FENC) insider files to sell 10,079 shares via option exercise - Stock Titan
Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Finviz
FENC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Adherex Technologies (FENC) to Release Quarterly Earnings on Monday - MarketBeat
FENC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
FENC Should I Buy - Intellectia AI
FENC SEC FilingsFennec Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Public market insider buying at Fennec Pharmaceuticals (FRX) - The Globe and Mail
(FRX) Investment Analysis and Advice (FRX:CA) - Stock Traders Daily
Quarterly Trades: Is ZVIA stock forming a cup and handleTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Portfolio Update: Can Fennec Pharmaceuticals Inc stock outperform in a bear marketEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Chipmakers Recap: Why is Fennec Pharmaceuticals Inc stock going down2025 Risk Factors & Precise Buy Zone Identification - baoquankhu1.vn
(FRX) Advanced Equity Analysis (FRX:CA) - Stock Traders Daily
Will Fennec Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Fennec Pharmaceuticals (FENC) and InfuSystem Holdings (INFU) - The Globe and Mail
Fennec Pharmaceuticals presents real-world data showing PEDMARK feasible, well tolerated in adults with head & neck cancer - TradingView
New PEDMARK real-world data in adult head & neck cancer from Fennec (NASDAQ: FENC) - Stock Titan
Is Fennec Pharmaceuticals Inc. still a buy after recent gainsRecession Risk & Advanced Swing Trade Entry Plans - mfd.ru
Fennec Showcases Real-World Data Backing PEDMARK Use in Adult Head and Neck Cancer - TipRanks
Fennec Pharmaceuticals Inc. Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK®? in Treating Adults with Head & Neck Cancers - marketscreener.com
Cancer drug timing tweak shows promise for preserving hearing - Stock Titan
Fennec Pharmaceuticals (FENC) CEO granted 13,710 shares as PSUs vest - Stock Titan
Fennec (NASDAQ: FENC) CFO adds shares via option exercise and PSU vesting - Stock Titan
(FRX) Investment Performance Report (FRX:CA) - Stock Traders Daily
When the Price of (FRX) Talks, People Listen (FRX:CA) - Stock Traders Daily
Will Fennec Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Macro Moves & Smart Swing Trading Techniques - mfd.ru
Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 10,349 Shares of Stock - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Upgraded to Strong-Buy at B.Riley Securit - MarketBeat
Adherex Technologies (NASDAQ:FENC) Upgraded at B.Riley Securit - MarketBeat
Adherex Technologies (NASDAQ:FENC) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Is Fennec Pharmaceuticals (TSX:FRX) Gaining Attention for Its Innovative Approach - Kalkine Media
Sentiment Recap: What are Fennec Pharmaceuticals Incs growth leversJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Can Fennec Pharmaceuticals Inc. stock double in the next year2025 Short Interest & Detailed Earnings Play Alerts - mfd.ru
Adherex Technologies (NASDAQ:FENC) Now Covered by Analysts at B. Riley Securities - Defense World
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50 - Defense World
Day Trade: Does Fennec Pharmaceuticals Inc have a sustainable dividendJuly 2025 Patterns & Expert Approved Momentum Ideas - baoquankhu1.vn
Will Fennec Pharmaceuticals Inc. (RV41) stock return to pre crash levelsJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - mfd.ru
Adherex Technologies (NASDAQ:FENC) Now Covered by B. Riley Securities - MarketBeat
B. Riley Initiates Fennec Pharmaceuticals at Buy With CA$21.69 Price Target - marketscreener.com
B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target - Investing.com UK
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Director |
Mar 02 '26 |
Sale |
8.36 |
10,079 |
84,260 |
103,996 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):